EUTOS Molecular Monitoring Structure  · 

Project structure

Lead investigators are:

• A. Hochhaus, University of Jena, Germany
• G. Saglio, University of Torino, Italy
• N.C.P. Cross, University of Southampton, U.K.
• Novartis representative: A. Covelli

The aim of this proposal is the integration of 50 European leukemia laboratories to

• establish molecular monitoring of residual disease according to standardized methods,
• optimize early detection of kinase mutations, including new very sensitive techniques,
• translate the obtained data into clinical application.

At least one laboratory per country or region should participate to serve as a national reference laboratory. Most of the participants have a longstanding cooperation across Europe and cooperate within the European LeukemiaNet. These participants are complemented by the integration of partner groups located in Australia and in US.
A prerequisite of European harmonization of molecular monitoring is that, beyond reaching a critical mass, virtually all leukemia study groups are apt for full implementation. The European LeukemiaNet provides a unique opportunity to distribute and test standards in the different branches of leukemia diagnostics including molecular monitoring and analysis of mechanisms of treatment resistance. This investment is highly cost-effective, reshapes the European infrastructure and achieves long lasting sustainability and added value.

Created by: Hellenbrecht , generated 2007/12/19 , last changed: 2009/09/15